$ALR (Alere Inc.)

$ALR {{ '2016-08-22T12:02:53+0000' | timeago}} • Announcement

Rapid diagnostics leader $ALR said its Alere i RSV test for detection of RSV infection in children and adults has received 510(k) marketing clearance from the US FDA. Alere i RSV is the first molecular test that can be used at point-of-care to detect RSV in 13 minutes or less.

$MDT {{ '2018-01-16T17:16:57+0000' | timeago}} • Announcement

$MDT received FDA clearance of the Riptide Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. This is designed to retrieve thrombus (or blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke.

$ILMN {{ '2018-01-16T12:42:12+0000' | timeago}} • Announcement

Luna DNA, the first and only genomic and medical research knowledge base powered by the blockchain and owned by its community, appointed Dawn Barry as president. Previously, Barry served as the VP of Applied Genomics at $ILMN.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$ABAX {{ '2018-01-09T17:20:52+0000' | timeago}} • Announcement

$ABAX reported preliminary financial results for 3Q18. Abaxis expects revenues in 3Q18 in a range of $59-60MM, an increase of 12-14% YoY. In addition, Abaxis expects operating income before income tax provision for this period of $9-10MM, compared to $10.8MM in last year's third quarter.

$ABAX {{ '2018-01-09T16:59:13+0000' | timeago}} • Announcement

$ABAX expects its effective income tax rate to decline by 200-300BP in FY18 vs. FY17, excluding a one-time non-cash charge related to the Tax Act. In 3Q18, $ABAX expects its effective income tax rate to be approx. 27%, excluding the one-time charge. $ABAX expects effective income tax rate in FY19 to be lower by 1,000-1,200BP vs. FY17.

$ABAX {{ '2018-01-09T16:58:58+0000' | timeago}} • Announcement

$ABAX expects revenues in 3Q18 to be $59-60MM, up 12-14%, over last year. $ABAX expects operating income before income tax provision of $9-10MM. The company expects GM to be 53.5-54%. During 3Q18, $ABAX expects to record a one-time non-cash charge of approx. $2.5-3.5MM as a result of the Tax Cuts and Jobs Act.

$TMO {{ '2018-01-09T12:43:22+0000' | timeago}} • Announcement

$TMO, a leading medical technology company, has signed an agreement with life sciences firm $ILMN, under which Thermo Fisher will provide Illumina with Ion AmpliSeq technology. The tie-up will help Illumina effectively sell Ion AmpliSeq technology to researchers engaged in scientific studies on its next-generation sequencing (NGS) platforms.

$NEOG {{ '2018-01-03T15:11:55+0000' | timeago}} • Announcement

Revenue of $NEOG rose 12% to $101.8MM in 2Q18. In the quarter, net income soared 53% to $17.1MM or $0.33 per diluted share, adjusted for a 4-for-3 stock split.

$MYGN {{ '2018-01-03T13:32:07+0000' | timeago}} • Announcement

$MYGN said $AZN will use its myChoice HRD Plus test in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza & Avastin. Under the agreement, $MYGN will use its myChoice Plus test to evaluate patients enrolled in an ongoing Phase III trial. Financial terms were not disclosed.

$NEOG {{ '2018-01-02T14:44:27+0000' | timeago}} • Announcement

$NEOG announced that all shares of its common stock will begin trading on a post-split basis to reflect the company’s 4-for-3 stock split. The price of the common stock will be adjusted downward by 25% from $82.21 to approx. $61.66 to account for the split. The adjusted price will be in effect on Jan. 2, 2018.

$ZBH {{ '2017-12-19T14:31:26+0000' | timeago}} • Announcement

$ZBH appointed Bryan Hanson as President and CEO and a member of the BoD, effective Dec. 19, 2017. Daniel Florin, who has served as Interim CEO since July 11, 2017, will continue in his role as SVP and CFO. Most recently, Hanson served as a $MDT's Executive Committee member and as EVP and President of Medtronic's Minimally Invasive Therapies Group.

$MDT {{ '2017-12-19T14:11:39+0000' | timeago}} • Announcement

$MDT has named Bob White, previously SVP and President of APAC Region, as EVP and President of Minimally Invasive Therapies Group. The company also announced Chris Lee, SVP and President of Greater China Region, will assume the position of APAC Region President. These leadership changes are effective immediately.

$ILMN {{ '2017-12-11T15:09:10+0000' | timeago}} • Announcement

$ILMN said Aimee Hoyt will head its human resources team. Hoyt will join as SVP and Chief People Officer (CPO), starting Jan. 8, 2018, and will be responsible for leading all aspects of the company’s HR strategies, reporting to CEO Francis deSouza.

$MDT {{ '2017-12-08T21:21:14+0000' | timeago}} • Announcement

$MDT BoD approved 3Q18 cash dividend of $0.46 per ordinary share, representing a 7% increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2017.

$NEOG {{ '2017-12-08T15:00:15+0000' | timeago}} • Announcement

$NEOG's BoD has approved a 4-for-3 stock split. As of Dec. 8, Neogen has about 38.63MM shares of common stock outstanding. After the split, the company will have about 51.5MM shares of common stock outstanding. This is the company's fifth stock split. The most recent was a 3-for-2 split in October 2013.

$NEOG {{ '2017-12-08T14:58:33+0000' | timeago}} • Announcement

$NEOG's BoD approved a 4-for-3 stock split. With the split, shareholders of record on Dec. 18, 2017, will receive 1 additional share of stock for each 3 shares held. The stock split will be effected in the form of new common stock being issued on Dec. 29, 2017, to shareholders of record as of the close of business on Dec. 18, 2017.

$DIS {{ '2017-12-08T11:53:58+0000' | timeago}} • Announcement

$DIS' BoD elected two new directors: Safra Catz, CEO of global-technology leader $ORCL, and Francis deSouza, President and CEO of biotechnology firm $ILMN. The elections of Catz and deSouza are effective Feb. 1, 2018.

$NEOG {{ '2017-12-06T17:42:58+0000' | timeago}} • Announcement

$NEOG announced that Ed Bradley, VP of the Food Safety division, has advised the company of his intentions to retire to pursue his personal interests. $NEOG has instituted a search for Bradley’s replacement, but in the meantime, he will continue to be available on a consulting basis to CEO John Adent.

$CLX {{ '2017-11-28T21:58:20+0000' | timeago}} • Announcement

$CLX announced the official opening of a new manufacturing facility for the company's Home Care products. Named Atlanta West, the 258,000-sq.ft. facility is adjacent to the company's existing manufacturing facility, called Atlanta Main. The opening of Atlanta West has created about 100 jobs in Clayton County.

$MDT {{ '2017-11-22T20:29:59+0000' | timeago}} • Webcast

In Oct., Animas announced to cease the manufacture and sale of its insulin pumps and partnered with $MDT to offer its customers the opportunity to transfer to a new device.With $JNJ exiting the insulin pump market in the US and Canada, $MDT now has access to the 90,000 patients who use Animas insulin pumps.

Recent Transcripts

NEOG (Neogen Corp.)
Wednesday, January 3 2018 - 4:00pm
MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
IMMU (Immunomedics Inc.)
Thursday, November 9 2017 - 10:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
KODK (Eastman Kodak Co.)
Wednesday, November 8 2017 - 10:00pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, November 8 2017 - 1:30pm
MYGN (Myriad Genetics, Inc.)
Tuesday, November 7 2017 - 9:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
GNMK (GenMark Diagnostics, Inc.)
Thursday, November 2 2017 - 8:30pm
QDEL (Quidel Corp.)
Wednesday, November 1 2017 - 9:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
CLX (The Clorox Company)
Wednesday, November 1 2017 - 5:30pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
QTNT (Quotient Limited)
Tuesday, October 31 2017 - 12:30pm
OXFD (Oxford Immunotec Global PLC)
Tuesday, October 31 2017 - 12:00pm
TRIB (Trinity Biotech plc)
Thursday, October 26 2017 - 3:00pm
LH (Laboratory Corp. of America Holdings)
Wednesday, October 25 2017 - 1:00pm
ILMN (Illumina Inc.)
Tuesday, October 24 2017 - 9:00pm

AlphaGraphics you may like